4 December 2014
TxCell announces start of phase IIb clinical trial with Ovasave® for refractory Crohn’s disease
TxCell SA (FR0010127662 – TXCL), a biotechnology company developing novel and innovative, cost-effective personalized T cell immunotherapies using antigen specific regulatory...